Table 1 Baseline characteristics
Characteristic | Number of patients |
|---|---|
Age (years) | |
Median (range) | 71 (53–91) |
PSA (ng/mL) | |
< 10 | 54 (36%) |
≥ 10 to < 20 | 47 (31.3%) |
≥ 20 | 49 (32.7%) |
Gleason Score | |
≤ 6 | 51 (34%) |
7 | 42 (28%) |
8 to 10 | 53 (35.3%) |
Clinical T stage | |
T1 | 27 (18%) |
T2 | 80 (53.3%) |
T3 | 39 (26%) |
T4 | 4 (2.7%) |
Lymph node metastasis | |
N0 | 135 (90%) |
N1 | 15 (10%) |
NCCN Risk Group | |
Low risk | 19 (12.7%) |
Intermediate risk | 49 (32.7%) |
High risk | 67 (44.6%) |
N1 disease | 15 (10%) |
Hormonal therapy | |
Yes | 149 (99.3%) |
No | 1 (0.7%) |
Follow-up time (months) | |
Median (range) | 68.9(2.3–172) |